KeyBanc analyst Scott Schoenhaus lowered the firm’s price target on R1 RCM to $13 from $18 and keeps an Overweight rating on the shares. The firm maintains longer-term positive bias on the HCIT sector, but believes demand trends for technology services for certain healthcare end markets are mixed in the near-term with ongoing concerns around the impacts of GLP-1s on both healthcare systems and employers’ benefit budgets, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RCM:
- ‘Profitability Is the Key’: Barclays Says These 3 Health Tech Stocks Are Poised for Growth
- Barclays starts healthcare technology, distribution with Neutral view
- R1 RCM initiated with an Overweight at Barclays
- R1 RCM to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- R1 RCM just upgraded at Morgan Stanley, here’s why